Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. - Wikidata - awgldk - TriplyDB

Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

http://www.wikidata.org/entity/Q33713908

about

Molecular imaging of oncolytic viral therapy Perspectives for therapeutic HPV vaccine development Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy Perspectives for preventive and therapeutic HPV vaccines.Immunotherapy for cervical cancer: Research status and clinical potential Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells Oncolytic virotherapy for ovarian cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Production of prostaglandin E₂ in response to infection with modified vaccinia Ankara virus Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial.Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy Effect of antipyretic analgesics on immune responses to vaccination.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Immunotherapeutic potential of oncolytic vaccinia virus.Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Current state in the development of candidate therapeutic HPV vaccines The Role of Myeloid-Derived Suppressor Cells in Viral Infection.Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

P2860

Q26999406-87792109-4727-4009-A3C7-DDFD04D15DEC Q28069272-F20227A1-3876-4209-95BB-86946D314ECF Q30411008-FD026785-8110-4335-AED7-FCEF7214E281 Q33822168-900807BE-A2AC-412B-BD69-56CB12D38D2C Q34011494-8C564856-BDCB-48D5-9CFE-ECD9C23AA379 Q34033763-D65E47F4-4550-40DC-AF4F-E1B7F54C3CD0 Q34726849-8E9BFEB0-7DCF-48AD-9B88-E25DE25E27B2 Q35184078-85659CE5-941B-4275-B401-FDDCA1A69134 Q35545752-59232CEC-1860-4C79-B2AE-58104E314CB8 Q35597082-B595C711-0C7B-4465-A74D-621B7E421568 Q35837949-F540A828-341F-4A99-B277-E11EC39B0253 Q35962511-E4CD9B17-31F5-49A9-A2D7-3D37058F7B7C Q36360872-84180D81-4F70-4E65-9975-E514BBD11C74 Q37181377-9BCA8987-F2A9-4D35-9C15-D47BDDD8BB7E Q37265004-01F3161D-8F28-4A1A-99E1-FF413CB70AE5 Q37899223-444E0882-7A4C-4D7E-B8E4-63418D930BD1 Q38225561-7A0E5D05-F4C2-4D89-8E9A-5483928540E9 Q38673968-34A6AA32-E16F-466B-B6D3-37538ACB4075 Q38743922-38659B1C-5890-4527-80DE-96A4EC9BA6ED Q38774994-2D39160E-EBDA-4DB6-AE89-09DD4ACF1CC5 Q39683647-87AC041A-13A8-40E6-AB05-2E1F1EBE5A39 Q50115667-0BCA1DD9-7AC2-4E73-9335-35B4C6473F26 Q58750585-22FE548C-BAD4-4012-B012-2EF72C8C80A0

P2860

Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer.

http://www.wikidata.org/entity/Q33713908

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@ast

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@en

type

label

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@ast

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@en

prefLabel

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@ast

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@en

P1433

Q33713908-96242EDC-1F5D-48F1-94DB-7ECF28DE2F2B

P1476

Q33713908-EC580E72-6660-4099-B679-5118B7C638EE

P2093

Q33713908-0BCFFEBB-1757-436D-B615-9A009EB119D5

Q33713908-6887BA08-F389-4AB7-A182-8DBFBA4467ED

Q33713908-8D20BD1A-B068-469F-99CF-63A91230E3FC

Q33713908-B082EB84-BB58-4C7C-8DF8-060724FA647A

Q33713908-DF437BC4-037B-45E2-82D5-EBBAAB9371D3

P2860

Q33713908-036E53EA-8FD9-4468-BA11-CBA2699CF115

Q33713908-0A6195F9-9CA9-4C70-A087-42C13791B85E

Q33713908-0EAC24CD-76C7-48DC-A04E-9ABCEE655D16

Q33713908-10BF9E76-1002-49B9-B8C6-76CC15687D91

Q33713908-1A286A29-B1A4-4FCD-934F-A410023D07FB

Q33713908-28B66AB4-FA28-4BD4-8E8D-5064E5CE75D8

Q33713908-2A38A840-92EF-4C6B-B944-92C1CB659B3E

Q33713908-3F4BE846-96E1-426C-B250-E6821AEACC20

Q33713908-3FF11239-4DE1-4919-A9ED-4A0C0883CEEE

Q33713908-4B8D5971-746C-4BB9-A1BC-7A91A569FF8A

P304

Q33713908-52264179-D800-48AF-89B7-4436CA4402FE

P31

Q33713908-C6CA693A-3338-49C5-A988-4B5A09D7BFB2

P356

Q33713908-5B054AC7-B0E4-4F6A-90C6-ADD00BF7C145

P433

Q33713908-4DD1E9B9-805D-4C62-99CB-3122E29DA4EA

P478

Q33713908-F3A6C6B6-3910-41F5-A1CD-3408B22954FA

P577

Q33713908-88C3BDA0-21A5-499B-8B58-BE028A4D19AD

P5875

Q33713908-65561288-B105-4048-A19C-8E9F7E2C3E0F

P698

Q33713908-4B1093FD-499F-4ACB-A25A-995EF8462A86

P921

Q33713908-1F91F15C-5E63-4505-B43E-88E5BC8E86C3

P932

Q33713908-3E4008BC-2F25-4ECB-BB47-32ED24349831

P356

P1433

Molecular Therapy

P1476

Treatment with cyclooxygenase- ...... for control of ovarian cancer.

@en

P2093

Barbara Ma

http://www.w3.org/2001/XMLSchema#string

Chien-Fu Hung

http://www.w3.org/2001/XMLSchema#string

Chih-Long Chang

http://www.w3.org/2001/XMLSchema#string

T-C Wu

http://www.w3.org/2001/XMLSchema#string

Xiaowu Pang

http://www.w3.org/2001/XMLSchema#string

P2860

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia

Cancer statistics, 2006

Administration of cyclooxygenase-2 inhibitor reduces joint inflammation but exacerbates osteopenia in IL-1 alpha transgenic mice due to GM-CSF overproduction.

Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Current diagnosis and treatment modalities for ovarian cancer.

Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?

P304

1365-1372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.118

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26242670

http://www.w3.org/2001/XMLSchema#string

P698

19471247

http://www.w3.org/2001/XMLSchema#string

P921

P932

2835247

http://www.w3.org/2001/XMLSchema#string